Prostate Neoplasm Clinical Trial
Official title:
Pilot Study: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radioligand therapy (RLT) using Lu-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are currently applied to treat metastatic castrate resistant prostate cancer (mCRPC) patients. However, there are no prospective studies published so far using this treatment approach in hormone sensitive setting. In this pilot study patients with hormone sensitive prostate cancer who did not undergo hormonal treatment will be treated with Lu-177 PSMA-617.
Radioligand therapy (RLT) is a promising new therapeutic approach to treat metastatic
prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane
antigen (PSMA), which is overexpressed in prostate cancer cells. In the last few years,
several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been developed and are
currently applied in nuclear medicine departments world-wide to treat metastatic castrate
resistant prostate cancer (mCRPC) patients.
A large retrospective study reported an overall biochemical response rate of 45% following
multiple 177Lu-PSMA RLT cycles in mCRPC patients, while 40% of patients already responded
after a single cycle. RLT with PSMA ligand PSMA-617 was generally well tolerated and 12% of
the patients suffered grade 3 to 4 hematological toxicity. In addition, mild and often
transient xerostomia occurred in 8%. These results were confirmed in a smaller scale
prospective study published recently.
Although these results are very promising, it is noteworthy that all currently
Lu-177-PSMA-617 RLT only has been evaluated in end stage prostate cancer patients to date. In
theory, RLT could be more effective in low volume disease because of the very high tumor
uptake of radioligands in small lesions. There are no published data so far evaluating the
therapeutic effect of Lu-177-PSMA-617 RLT in an earlier stage of the disease. Because of the
difference in tumor load between mCRPC patients and patients with low volume metastatic
disease, dosimetry and toxicity in these patients need evaluation. Here a clinical trial to
investigate the efficacy of Lu-177-PSMA-617 RLT in patients with low volume metastatic
prostate cancer, prior to the hormone insensitive state is proposed.
Objective: The aim of this study is to evaluate the dosimetry and toxicity of Lu-177-PSMA-617
RLT, in patients with low volume, hormone sensitive metastatic prostate cancer under
treatment condition. Ultimately, the goal of this study is to stabilize previously
progressive disease in these patients and to improve the quality of life by postponing the
need for androgen deprivation therapy (ADT).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06315595 -
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion
|
||
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00255125 -
Role of Soy Supplementation in Prostate Cancer Development
|
Phase 3 | |
| Terminated |
NCT02809690 -
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
|
Phase 1 | |
| Completed |
NCT06020287 -
The Robot-Assisted Laparoscopic Radical Prostatectomy Combined Anterior and Posterior Approach
|
||
| Recruiting |
NCT03572946 -
Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection
|
N/A | |
| Active, not recruiting |
NCT03344757 -
Health Gatherings - For Your Health After Cancer
|
N/A | |
| Recruiting |
NCT05137561 -
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy
|
N/A | |
| Recruiting |
NCT04792138 -
Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
|
||
| Completed |
NCT03702439 -
Prostate Cancer Screening Trial Using Imaging
|
||
| Completed |
NCT04852224 -
Strength, Aging, and Memory in Prostate Cancer
|
||
| Completed |
NCT01240551 -
F-18 Sodium Fluoride in Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
| Recruiting |
NCT02436122 -
Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer
|
N/A | |
| Active, not recruiting |
NCT03493945 -
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
|
Phase 1/Phase 2 | |
| Completed |
NCT04376008 -
A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia
|
N/A | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06292897 -
Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
|
||
| Recruiting |
NCT03819751 -
MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection
|
N/A | |
| Not yet recruiting |
NCT05460312 -
Protein Kinase A in Prostate Cancer Tissue.
|